➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Johnson and Johnson
Medtronic
Merck

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,497,284

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,497,284 protect, and when does it expire?

Patent 8,497,284 protects CABOMETYX and is included in one NDA.

This patent has seventy patent family members in sixteen countries.

Summary for Patent: 8,497,284
Title:C-met modulators and method of use
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s): Bannen; Lynne Canne (Lucerne, CA), Chan; Diva Sze-Ming (Oakland, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (Seattle, WA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (San Mateo, CA), Leahy; James William (San Leandro, CA), Mac; Morrison B. (San Francisco, CA), Mann; Grace (San Mateo, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Foster City, CA), Xu; Wei (Danville, CA)
Assignee: Exelixis, Inc. (South San Francisco, CA)
Application Number:13/249,815
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,497,284
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,497,284

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-001 Apr 25, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF RENAL CELL CARCINOMA   Start Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-001 Apr 25, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB   Start Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-001 Apr 25, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF ADVANCED RENAL CELL CARCINOMA   Start Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF RENAL CELL CARCINOMA   Start Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF ADVANCED RENAL CELL CARCINOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Colorcon
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.